Corporate Liability For Systemic Bribery In Healthcare Procurement
1. Introduction: Corporate Liability in Systemic Bribery in Healthcare Procurement
Systemic bribery in healthcare procurement occurs when corporations offer, give, or facilitate bribes to influence the awarding of contracts for medical supplies, pharmaceuticals, or hospital services. Such actions undermine public trust, inflate healthcare costs, and can endanger patient safety.
Legal Framework
Domestic Laws
Anti-Corruption Statutes: Most jurisdictions criminalize bribery in public procurement. Examples:
U.S. Foreign Corrupt Practices Act (FCPA)
UK Bribery Act 2010
Indian Prevention of Corruption Act, 1988
Corporations can face both criminal liability and civil penalties.
International Legal Instruments
OECD Anti-Bribery Convention (1997)
UN Convention Against Corruption (2003)
Key Elements
Offering, giving, or receiving a bribe to influence procurement.
Corporate knowledge or facilitation of bribery.
Systemic nature: Regular or widespread practice across multiple contracts or regions.
2. Case Law Illustrations
Case 1: GlaxoSmithKline (GSK) – China, 2014
Facts:
GSK executives were accused of systemically bribing healthcare professionals and hospitals to promote their drugs.
Bribes included cash, travel, and gifts to influence procurement and prescriptions.
Holding:
GSK pled guilty in Chinese courts.
Company fined nearly $490 million, and executives faced imprisonment.
Key Takeaways:
Corporations can be held liable for bribery conducted through local subsidiaries.
Penalties include fines, imprisonment of responsible individuals, and reputational damage.
Case 2: Pfizer Inc. – Italy, 2012
Facts:
Pfizer was accused of offering bribes to Italian healthcare officials to secure drug procurement contracts for vaccines and medicines.
Holding:
Italian prosecutors found Pfizer liable; executives faced criminal charges.
Company settled through financial penalties and compliance commitments.
Key Takeaways:
Bribery in procurement contracts can trigger both criminal and civil liability.
Corporate liability arises from direct and indirect facilitation of bribes.
Case 3: Novartis – Greece, 2018
Facts:
Novartis allegedly engaged in systemic bribery to influence hospital procurement and reimbursements for their products.
Holding:
Greek authorities conducted investigations under anti-corruption and anti-fraud statutes.
Some executives faced criminal charges; Novartis agreed to internal reforms and monitoring programs.
Key Takeaways:
Even investigations without full convictions can impose reputational and operational constraints.
Corporate compliance programs are critical to prevent procurement bribery.
Case 4: Teva Pharmaceuticals – U.S., 2020
Facts:
Teva executives were charged with bribing doctors and hospital officials to prescribe specific medications, indirectly influencing procurement contracts.
Holding:
Teva agreed to pay $519 million in settlements to U.S. authorities under the FCPA and anti-kickback statutes.
Individuals involved faced fines and imprisonment.
Key Takeaways:
Systemic bribery in healthcare procurement can also be prosecuted under anti-kickback laws in addition to bribery statutes.
Corporate settlements often include mandatory compliance monitoring.
Case 5: Johnson & Johnson – China, 2013–2016
Facts:
J&J subsidiaries allegedly bribed hospital officials to promote medical devices and drugs, influencing procurement.
Holding:
Chinese authorities fined J&J over $100 million, and multiple local executives were jailed.
Key Takeaways:
Liability extends to foreign subsidiaries if they engage in bribery.
Global corporations face cross-border anti-bribery enforcement.
Case 6: Sandoz (Novartis) – India, 2016
Facts:
Sandoz allegedly systemically offered inducements to doctors and hospitals to secure contracts for antibiotics and other drugs.
Holding:
Investigations by the Central Bureau of Investigation (CBI) led to criminal proceedings against executives.
Company implemented strict compliance and monitoring programs.
Key Takeaways:
Indian law punishes systemic bribery in healthcare procurement with imprisonment and fines.
Corporate liability includes policies, monitoring failures, and complicity of senior management.
3. Principles Derived from Case Law
Corporate Knowledge and Facilitation: Liability arises when corporations knowingly authorize or facilitate bribes.
Systemic Nature Increases Penalty: Repeated or widespread bribery leads to heavier fines and sanctions.
Subsidiary and Cross-Border Liability: Parent companies can be held accountable for the actions of subsidiaries abroad.
Combination with Other Laws: Anti-kickback statutes, fraud laws, and FCPA/Bribery Act statutes can apply.
Compliance Programs Mitigate Risk: Courts and regulators consider internal compliance programs when assessing penalties.
4. Conclusion
Systemic bribery in healthcare procurement exposes corporations to criminal, civil, and reputational liability. Courts worldwide increasingly hold corporations accountable, especially when bribery affects public health, procurement integrity, and financial transparency.
Key Takeaways:
Liability includes financial penalties, imprisonment of executives, and mandatory compliance reforms.
Companies must implement robust anti-bribery programs across all subsidiaries.
RELATED Blog
comments